Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VXA CoV2 1

Drug Profile

VXA CoV2 1

Alternative Names: Corona virus vaccine - VAXART; COVID-19 (SARS-CoV-2) E1-/E3-deleted replication defective recombinant adenovirus 5 with dsRNA adjuvant oral tablet vaccine; Non replicating Ad5 adjuvanted oral tableted vaccine; Oral SARS-CoV2 vaccine; Oral Tableted Ad5 COVID-19 Vaccine; SARS-CoV2 vaccine - VAXART; VXA-CoV2-1

Latest Information Update: 28 Oct 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaxart
  • Class COVID-19 vaccines; Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported COVID 2019 infections

Most Recent Events

  • 28 Oct 2023 No recent reports of development identified for phase-I development in COVID-2019-infections(In the elderly, Prevention, In adults) in USA (PO, Tablet)
  • 20 Jul 2022 Updated immunogenicity data from a phase I trial in COVID-2019 infections released by Vaxart
  • 24 Feb 2022 Pharmacodynamic data from a preclinical trial in COVID-2019 infections released by Vaxart
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top